1. Step 9
1.1. Review session 2
1.2. mechanism flow chart
1.3. 20 minutes
2. Step 10
2.1. Management (for the individual)
2.1.1. Goals of therapy
2.1.1.1. clinical improvement
2.1.1.2. stablization
2.1.1.3. reduction in mortality
2.1.2. Pharmacological
2.1.2.1. Diuritics
2.1.2.1.1. Reduce preload
2.1.2.1.2. Types
2.1.2.1.3. Side effects
2.1.2.1.4. Goals
2.1.2.1.5. Diuritics resistance
2.1.2.2. ACE inhibitors
2.1.2.2.1. Prognosis
2.1.2.2.2. Function
2.1.2.2.3. Sideeffects
2.1.2.3. ARBs
2.1.2.3.1. Used if ACE inhibitors is contraindicated
2.1.2.3.2. Difference between ACE in. is the absence of COUGH.
2.1.2.4. Aldosterone Antagonist
2.1.2.5. Beta blocks
2.1.2.5.1. Generation
2.1.2.5.2. Function
2.1.2.5.3. Contraindication
2.1.2.6. Anticoagulants
2.1.2.6.1. Used as prophylaxis (admitted patients)
2.1.2.6.2. Heparin
2.1.2.7. Nitrates
2.1.2.7.1. Hedralazane
2.1.2.7.2. Function
2.1.3. Nonpharmacological
2.1.3.1. Alcohol cessation
2.1.3.1.1. May help in making the patent better
2.1.3.1.2. May not work if disease is in late stage
2.1.3.2. Diet and nutrition
2.1.3.2.1. Important to educate
2.1.3.2.2. Decrease salt intake
2.1.3.2.3. If from ischemia(not our case)-->they should reduce fatty food
2.1.3.2.4. Consider having multidisciplinary teams
2.1.3.3. Aerobic excercise
2.1.3.3.1. 2012 meta analysis
2.1.3.4. Smoking cessation
2.1.3.5. Weight reduction
2.1.3.5.1. maintain 10% of ideal weight
2.1.3.6. Implanted cardiac defrillator
2.1.3.6.1. Criteria
2.1.3.7. CRT
2.1.3.7.1. Ejection fraction less than 35%
2.1.3.7.2. Class III and IV
2.1.3.7.3. Bi-ventricular
2.1.3.8. Surgical treatment
2.1.3.8.1. Heart transplant
2.1.3.8.2. Gold standard treatment
2.1.3.8.3. Problem in finding a typical heart that fits the patient
2.1.3.8.4. Ventricular asses device
2.1.4. prognosis
2.2. Prevention (for the population)
2.2.1. Control chronic diseases
2.2.2. Campaign about alcohol toxicity
2.2.3. Screening
2.2.4. Educate the population about healthy lifestyle
2.2.5. Restrictions